AR071908A1 - Compuesto triazina, composiciones que lo comprenden, metodo para elaborar el compuesto y metodo para tratar un trastorno de tipo cancerigeno - Google Patents

Compuesto triazina, composiciones que lo comprenden, metodo para elaborar el compuesto y metodo para tratar un trastorno de tipo cancerigeno

Info

Publication number
AR071908A1
AR071908A1 ARP090101878A ARP090101878A AR071908A1 AR 071908 A1 AR071908 A1 AR 071908A1 AR P090101878 A ARP090101878 A AR P090101878A AR P090101878 A ARP090101878 A AR P090101878A AR 071908 A1 AR071908 A1 AR 071908A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heterocyclyl
amino
membered
Prior art date
Application number
ARP090101878A
Other languages
English (en)
Inventor
Ariamala Gopalsamy
Kevin J Curran
Santos Osvaldo Dos
Zecheng Chen
Aranapakam Venkatesan
Mengxiao Shi
Tarek S Mansour
J Verheijen
Semiramis Ayral-Kaloustian
Arie Zask
Joshua Aaron Kaplan
David James Richard
Los Santos Efren Guillermo De
Christoph M Dehnhardt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071908(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR071908A1 publication Critical patent/AR071908A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Estos compuestos inhiben la quinasa PI3 y mTOR, y se pueden utilizar para tratar enfermedades mediadas por quinasa PI3 e y mTOR, tal como una variedad de c nceres. Y metodos para elaborar y utilizar los compuestos de esta solicitud y composiciones que contienen los compuestos de esta solicitud. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque: R1es como en formulas (2) o (3) en donde R6, R7, R8, R9 son cada uno independientemente seleccionados del grupo que consiste de un  tomo de hidrogeno, y un alquilo C1-6 opcionalmente sustituido con alquenilo C2-6, alcadienilo C4-6, alquinilo C2-6 o alcadiinilo C4-6, o uno de R6 y R7 o R8 y R9, junto con los  tomos de carbono a los cuales ellos se adhieren forman un anillo saturado o insaturado de 5-8 miembros opcionalmente sustituido conteniendo 0, 1 o 2  tomos independientemente seleccionados de O, NH y S; la l¡nea intermitente ------- representa un segundo enlace opcional; R2 es arilo C6-14 opcionalmente sustituido-NH-COR3, heteroarilo C1-9 opcionalmente sustituido-NH-COR3, -CH=CH-arilo C6-10-NH-COR3 o -CH=CH-heteroarilo C1-9-NH-COR3; R3 es OR5, NR5R5 o NHR5; R5 se selecciona independientemente del grupo que consiste de alquilo C1-6, alquenilo C3-6, alquinilo C3-6, arilo C6-10 opcionalmente sustituido, haloalquilo C1-6, heteroarilo C1-9 opcionalmente sustituido, hidroxialquilo C1-6, cicloalquilo C3-10 saturado o C3-10 mono o bic¡clico insaturado opcionalmente sustituido con OH, NR11R11 o heterociclilo C1-6 de 3-7 miembros, y heterociclilo C1-9 mono o bic¡clico saturado o insaturado de 3-10 miembros; con la condicion que anillos cicloalquilo y heterociclilo de tres miembros son saturados; o dos grupos R5 tomados juntos con el  tomo de nitrogeno al cual ellos se adhieren para formar un sistema de anillo de 3 a 8 miembros opcionalmente sustituido con alquilo C1-6, cuyo sistema de anillo es saturado o insaturado y tiene, en adicion a dicho  tomo de nitrogeno, 0 a 2 hetero tomos miembros del anillo seleccionados de O, S, S(O), S(O)2 y NR10; R10 se selecciona del grupo que consiste de H, alquilo C1-6, -SO2(alquilo C1-6), -COO(alquilo C1-6), -CONH(alquilo C1-6), -CON(alquilo C1-6)2, -CO(alquilo C1-6), y -SO2NHR11; R11 se selecciona del grupo que consiste de H, alquilo C1-6 opcionalmente sustituido con OH, NR11R11 o a heterociclilo C1-6 de 3-7 miembros, -CO(alquilo C1-6), arilo C6-10 opcionalmente sustituido, y heteroarilo C1-9 opcionalmente sustituido; R4 se selecciona del grupo que consiste de: a) alquilo C1-6 opcionalmente sustituido con: i) heterociclilo C1-9 de 3-10 miembros opcionalmente sustituido con alquilo C1-6-, ii) H2N-, iii) (alquilo C1-6)NH-, iv) (alquilo C1-6)2N-, y) NH(CH2)aN(alquilo C-16)2 en donde a es 2, 3 o 4, y vi) CHO, b) alquenilo C3-6, c) alquinilo C3-6, d) -O-alquilo C1-8 opcionalmente sustituido con -O-alquilo C1-8, e) -O-alquenilo C3-8, f) -O-alquinilo C3-8, g) cicloalquilo C3-8 mono o bic¡clico saturado o insaturado; y -h) -O-cicloalquilo C3-12 mono o bic¡clico saturado o insaturado, todos los anteriores opcionalmente sustituidos con OH, NR11R11 o un heterociclilo C1-6 de 3-7 miembros opcionalmente sustituido con alquilo C1-6-, dado que un OH o NR11R11 no se une directamente en un  tomo de carbono que se une doble o triple a otro  tomo de carbono; i) -CH=CH-arilo C6-10; j)-CH=CH-heteroarilo C1-9, k) arilo C6-10 opcionalmente sustituido; l) heteroarilo C1-9 de 5-10 miembros opcionalmente sustituido adherido al grupo funcional triazina por v¡a del  tomo de carbono; m) heteroc¡clico C1-9 monoc¡clico saturado o insaturado de 3-10 miembros adherido al grupo funcional triazina a traves de un  tomo de nitrogeno o carbono y opcionalmente sustituido con de 1 a 3 sustituyentes seleccionados independientemente de: OH, NR11R11, alquilo C1-6, (alquilo C1-6)amido-, (alquilo C1-6)C(O)-, (alcoxi C1-6)carbonil-, adamantilo, hidroxialquilo C1-6-, (alquilo C1-6)amido-, o un heterociclilo C1-6 de 3-7 miembros, con la condicion que el heterociclilo de 3 miembros se satura y se adhiere al grupo funcional triazina a traves de un  tomo de nitrogeno, y el heterociclilo bic¡clico de 5 miembros se satura; n) -O-arilo C6-10 opcionalmente sustituido; o) -O-heteroarilo C1-9 opcionalmente sustituido; p) -O-heterociclilo C1-9 (mono o bic¡clico saturado o insaturado de 3-12 miembros) opcionalmente sustituido con (alcoxi C1-6)carbonil-, H2NS(O)2, o alquilo C1-6 adicionalmente opcionalmente sustituido con OH, NR11R11 o un heterociclilo C1-6 de 3-7 miembros, con la condicion que se sature el heterociclilo de tres miembros; q) -NHarilo C6-10, r) -NHheteroarilo C1-9, s) -NHNH2, t) -NHNHalquilo C1-6, u) -NHN(alquilo C1-6)2, v) -NHOH, w) -COOH, x) COO-alquilo C1-6, y) -CONR12R13, z) -NR12R13, el grupo de formulas (4) en donde Z es CH2, O, S(O)n o NR10 y n es 0, 1 o 2; ee) halogeno, ff) arilo C6-14-S(O)2NH-, gg) R11NHC(O)NH-O-, y hh) heteroarilo C1-4 monoc¡clico de 5 miembros opcionalmente sustituido adherido al grupo funcional triazina por v¡a de un  tomo de nitrogeno; R12 y R13 se seleccionan cada uno independientemente de H, alquilo C1-8 opcionalmente mono o disustituido, alquenilo C3-8 opcionalmente sustituido, y alquinilo C3-8 opcionalmente sustituido, los sustituyentes opcionales se seleccionan de alcoxi C1-6, OH, NR11R11, y heterociclilo C1-6 de 3-7 miembros, dado que un OH o NR11R11 no se une directamente en un  tomo de carbono que se une doble o triple a otro  tomo de carbono; o R12 y R13 tomados junto con el  tomo de nitrogeno al cual ellos se adhieren forman un sistema de anillo monoc¡clico de 3 a 8 miembros opcionalmente sustituido con alquilo C1-6, cuyo sistema de anillo es saturado o insaturado y tiene, en adicion a dicho  tomo de nitrogeno, 0 a 2 hetero tomos miembros del anillo seleccionados de O, S(O)n y NR10; o R12 y R13 tomados junto con el  tomo de nitrogeno al cual ellos se adhieren forman un compuesto como en formulas (5) en donde a y b son cada uno independientemente -CH2-, O, S, o NR10, y x es 1-3; heteroarilo C1-9 se refiere a un sistema de anillo arom tico de 5-10 miembros que tiene uno o m s anillos y 1, 2, 3 o 4 miembros del anillo independientemente seleccionados de O, NR10, y S(O)n; heterociclilo C1-9 se refiere a un sistema de anillo de 3-10 miembros que tiene uno o m s anillos y 1, 2, 3 o 4 miembros de anillo independientemente seleccionados de O, NR10, y S(O)n; y los grupos arilo y heteroarilo opcionalmente sustituidos son no sustituidos o sustituidos con 1 o 2 grupos funcionales seleccionados del grupo que consiste de: a) alquilo C1-6 opcionalmente sustituido con OH, NH2, NH(alquilo C1-6), N(alquilo C1-6)2, -NH(CH2)wN(alquilo C1-6)2 en donde w es 2, 3 o 4, o heterociclilo C1-9 de 3-10 miembros opcionalmente sustituido con de 1 a 3 sustituyentes alquilo C1-6 seleccionados independientemente; b) halogeno; c) hidroxi; d) NH2 e) NO2 f) SO2NH2 g) COOH; h) COO(alquilo C1-6); i) NHCOO(alquilo C1-6); j) NH(alquilo C1-6); k) N(alquilo C1-6)2, l) C(O)NRaRb, en donde Ra es H o alquilo C1-6, y Rb es H, alquilo C1-6, (arilo C6-14)alquil-, o (heteroarilo C1-9)alquil-; m) Y-Q, en donde y es : i) O, ii) NH, iii) N(alquilo C1-6), iv) NHSO2, v) SO2NH, vi) NHCONH, vii) NHCON(alquilo C1-6), viii) S(O)q, q es 0 1 o 2, ix) -C(O)NH-, x) -C(O)N(CH3)-, xi) -NHC(O)-, xii) C(O), o xiii) ausente, y Q se selecciona de: i) arilo C6-10, opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: A) alcoxi C1-6- opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, 3) di(alquilo C1-6)amino-, 4) heterociclilo C1-9- opcionalmente sustituido por alquilo C1-6-, o 5) hidroxilo, B) (alcoxi C1-6)carbonil-, C) (alcoxi C1-6)C(O)NH-, D) alquilo C1-6- opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, o 3) di(alquilo C1-6)amino-, E) (alquilo C1-6)amino-, F) di(alquilo C1-6)amino-, G) (alquilo C1-6)amido- opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, o 3) di(alquilo C1-6)amino-, H) (alquilo C1-6)carboxiamido-, l) heterociclilo C1-9- opcionalmente sustituido por alquilo C1-6- o hidroxialquilo C1-6-, J) heterociclilo(alquilo C1-6)- opcionalmente sustituido por alquilo C1-6-, K) halogeno. L) hidroxilo, M) hidroxialquilo C1-6-, N) perfluoroalquilo C1-6-, O) H2N-, P) O2N-, Q) H2NSO2-, R) HO2C-, y S) NC-, ii) heteroarilo C1-9 de 5-10 miembros, opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: A) alcoxi C1-6 opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, 3) di(alquilo C1-6)amino-, 4) heterociclilo C1-9- opcionalmente sustituido por alquilo C1-6-, o 5) hidroxilo, B) (alcoxi C1-6)carbonil-, C) (alcoxi C1-6)C(O)NH-, D) alquilo C1-6- opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, o 3) di(alquilo C1-6)amino-, E) (alquilo C1-6)amino-, F) di(alquilo C1-6)amino-, G) (alquilo C1-6)amido- opcionalmente sustituido con 1) H2N-, 2) (alquilo C1-6)amino-, o 3) di(alquilo C1-6)amino-, H) (alquilo C1-6)carboxiamido-, I) heterociclilo C1-9- opcionalmente sustituido por alquilo C1-6- o hidroxialquilo C1-6, J) heterociclilo(alquilo C1-6)- opcionalmente sustituido por alquilo C1-6-, K) halogeno, L) hidroxilo, M) hidroxialquilo C1-6-, N) perfluoroalquilo C1-6-, O) H2N-, P) O2N-, Q) H2NSO2, R) HO2C-, y S) NC-, iii) heterociclilo C1-9 de 3-10 miembros, opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: A) alquilo C1-6-, B) heterociclilo(alquilo C1-6)-, C) (arilo C6-14)alquil-, D) acilo C1-8-, E) (alcoxi C1-6)carbonil-, F) (alquilo C1-6)carboxil-, G) halogeno, H) haloalquilo C1-6, I) hidroxilo, J) hidroxialquilo C1-6-, K) H2N-, L) (alquilo C1-6)amino-, M) di(alquilo C1-6)amino-, N) HO2C-, O) (alcoxi C1-6)carbonil-, P) (alquilo C1-6)carboxil-, Q) (alquilo C1-6)amido-, R) H2NC(O)-, S) (alquilo C1-6)carboxiamido-, T) heteroarilo C1-9 de 5-10 miembros, U) arilo C6-14, V) cicloalquilo C3-8, W) heterociclilo C1-9 de 3-10 miembros, X) NC-; y Y) -NO2 iv) cicloalquilo C3-10, v) alquilo C1-6, vi) alquenilo C2-6, vii) alquinilo C2-6, viii) hidroxial
ARP090101878A 2008-05-23 2009-05-26 Compuesto triazina, composiciones que lo comprenden, metodo para elaborar el compuesto y metodo para tratar un trastorno de tipo cancerigeno AR071908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5566108P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
AR071908A1 true AR071908A1 (es) 2010-07-21

Family

ID=40911929

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090101879A AR071909A1 (es) 2008-05-23 2009-05-26 Compuesto triazina, composicion que lo comprende y metodo para elaborar el compuesto
ARP090101878A AR071908A1 (es) 2008-05-23 2009-05-26 Compuesto triazina, composiciones que lo comprenden, metodo para elaborar el compuesto y metodo para tratar un trastorno de tipo cancerigeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090101879A AR071909A1 (es) 2008-05-23 2009-05-26 Compuesto triazina, composicion que lo comprende y metodo para elaborar el compuesto

Country Status (43)

Country Link
US (8) US8039469B2 (es)
EP (3) EP2294072B1 (es)
JP (2) JP2011520979A (es)
KR (1) KR101331341B1 (es)
CN (2) CN102036995B (es)
AP (2) AP2775A (es)
AR (2) AR071909A1 (es)
AU (2) AU2009248993C1 (es)
BR (1) BRPI0912294B8 (es)
CA (2) CA2721710A1 (es)
CL (2) CL2009001273A1 (es)
CO (1) CO6311070A2 (es)
CR (1) CR11757A (es)
CU (1) CU23887B1 (es)
CY (2) CY1118879T1 (es)
DK (2) DK2294072T3 (es)
DO (1) DOP2010000315A (es)
EA (1) EA020317B1 (es)
EC (2) ECSP10010624A (es)
ES (2) ES2728163T3 (es)
GE (1) GEP20125589B (es)
HR (2) HRP20170637T1 (es)
HU (1) HUE043331T2 (es)
IL (2) IL209060A (es)
LT (2) LT3216793T (es)
MA (1) MA32319B1 (es)
ME (1) ME01111B (es)
MX (1) MX2010012808A (es)
MY (1) MY155653A (es)
NI (1) NI201000198A (es)
NZ (1) NZ588526A (es)
PA (2) PA8828201A1 (es)
PE (2) PE20091943A1 (es)
PL (1) PL3216793T3 (es)
PT (2) PT2294072T (es)
RS (2) RS58724B1 (es)
SA (1) SA109300314B1 (es)
SI (2) SI2294072T1 (es)
TR (1) TR201906123T4 (es)
TW (2) TW201008949A (es)
UA (1) UA99361C2 (es)
WO (2) WO2009143313A1 (es)
ZA (1) ZA201007204B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022381B2 (en) * 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
JP5351254B2 (ja) 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
AU2009248993C1 (en) * 2008-05-23 2013-10-03 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
WO2011087812A1 (en) * 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
EA201300867A1 (ru) * 2011-01-27 2014-03-31 Дзе Трастиз Оф Принстон Юнивесити ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
CA2849189A1 (en) * 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
JP5995977B2 (ja) 2011-10-07 2016-09-21 セルゾーム リミテッド Ｍｔｏｒ阻害剤としてのモルホリノ置換二環式ピリミジン尿素またはカルバメート誘導体
CN102659765B (zh) * 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
WO2014005182A1 (en) * 2012-07-04 2014-01-09 Monash University Phosphoinositide 3-kinase (pi3k) inhibitors
US9630958B2 (en) 2012-07-23 2017-04-25 Sphaera Pharma Pte. Ltd. Triazine compounds
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
ES2834927T3 (es) 2014-03-14 2021-06-21 Pfizer Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
US20170273922A1 (en) * 2014-10-03 2017-09-28 The Royal Institution For The Advacement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
WO2016055907A1 (en) * 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
CN107428730B (zh) 2014-11-20 2020-10-16 科学与工业研究会 作为抗癌试剂的1,3,5-三嗪基pi3k抑制剂及其制备方法
PL3233054T3 (pl) * 2014-12-17 2021-12-20 Pfizer Inc. Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego
CN104725361B (zh) * 2015-04-09 2017-05-31 江苏富比亚化学品有限公司 一种受阻胺类光稳定剂3346的制备方法
CN109311825B (zh) 2016-05-12 2022-03-22 南京世其医药科技有限公司 2,4,6-三取代均三嗪化合物及其制备方法和应用
KR102472461B1 (ko) 2016-05-18 2022-11-30 토르쿠르 아게 신경 질환의 치료
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
IT201700047189A1 (it) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
WO2019036489A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. COMBINATION THERAPY
ES2895370T3 (es) 2017-08-25 2022-02-21 Pfizer Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
KR102022323B1 (ko) * 2018-03-30 2019-09-18 정하윤 트리아진 화합물 및 이의 용도
SI3810089T1 (sl) * 2018-06-07 2023-11-30 Pfizer Inc. Vodna formulacija,ki vsebuje 1-(4-((4-(dimetilamino)piperidin-1-il)karbonil)fenil)-3-(4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil)sečnino
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109942562B (zh) * 2019-02-27 2022-02-08 江西科技师范大学 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
WO2021207024A1 (en) * 2020-04-07 2021-10-14 Mei Pharma, Inc. Preparation of a 1,3,5-triazinyl benzimidazole
JP2024504378A (ja) * 2021-01-25 2024-01-31 アトス セラピューティクス，インコーポレイテッド トリアジン化合物ならびにこれを作製する方法および使用する方法
KR20220138575A (ko) 2021-04-06 2022-10-13 부산대학교병원 전좌 신장암 치료 또는 예방용 약물 스크리닝 방법
CN113200969B (zh) * 2021-05-19 2022-11-25 中国药科大学 一种PI3Kα选择性抑制剂及其制备方法和应用
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
CN115109049B (zh) * 2022-08-12 2023-08-15 江西科技师范大学 含芳基脲结构的三嗪类化合物及其应用
CN115557908B (zh) * 2022-09-28 2024-10-15 九江学院 一种含硫连接键的三嗪类衍生物及其合成方法、用途
CN116102545B (zh) * 2023-02-01 2025-03-25 贵州医科大学 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
CN116239580B (zh) * 2023-03-06 2025-05-23 中国药科大学 三嗪类化合物及其制备方法、药物组合物和应用
WO2025116280A1 (ko) * 2023-11-29 2025-06-05 주식회사 펩토이드 새로운 대칭형 플루오로트리아진 화합물 및 이들의 의학적 또는 생물학적 용도
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
WO2026044119A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition
CN120004875A (zh) * 2025-04-22 2025-05-16 中国药科大学 靶向降解磷脂酰肌醇3-激酶的化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129597C (zh) * 1997-07-24 2003-12-03 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤剂
AU1818599A (en) * 1997-12-12 1999-07-05 Abbott Laboratories Triazine angiogenesis inhibitors
US7071189B2 (en) * 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
JP5534811B2 (ja) 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
AU2009248993C1 (en) * 2008-05-23 2013-10-03 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors

Also Published As

Publication number Publication date
KR101331341B1 (ko) 2013-11-19
MA32319B1 (fr) 2011-05-02
EP3216793B1 (en) 2019-03-27
MY155653A (en) 2015-11-13
JP2011520979A (ja) 2011-07-21
ES2625467T3 (es) 2017-07-19
HRP20170637T1 (hr) 2017-06-30
NI201000198A (es) 2011-05-09
WO2009143317A1 (en) 2009-11-26
DOP2010000315A (es) 2010-12-15
PL3216793T3 (pl) 2019-09-30
US20110312955A1 (en) 2011-12-22
EP3216793A1 (en) 2017-09-13
IL209060A (en) 2014-05-28
PT2294072T (pt) 2017-05-29
EP2294072A1 (en) 2011-03-16
US9174963B2 (en) 2015-11-03
CL2009001274A1 (es) 2009-10-16
CA2721692A1 (en) 2009-11-26
LT2294072T (lt) 2017-06-12
US20140248239A1 (en) 2014-09-04
US8039469B2 (en) 2011-10-18
SA109300314B1 (ar) 2012-09-26
US20130315865A1 (en) 2013-11-28
UA99361C2 (uk) 2012-08-10
PA8828101A1 (es) 2009-12-16
CN102036995B (zh) 2014-09-17
CY1118879T1 (el) 2018-01-10
WO2009143313A1 (en) 2009-11-26
LT3216793T (lt) 2019-05-10
ECSP10010624A (es) 2010-12-30
EP2294072B1 (en) 2017-03-29
HUE043331T2 (hu) 2019-08-28
US8575159B2 (en) 2013-11-05
SI2294072T1 (sl) 2017-05-31
PE20091943A1 (es) 2009-12-19
US8859542B2 (en) 2014-10-14
BRPI0912294B8 (pt) 2021-05-25
SI3216793T1 (sl) 2019-06-28
AP2775A (en) 2013-09-30
CN102036995A (zh) 2011-04-27
RS55960B1 (sr) 2017-09-29
MX2010012808A (es) 2010-12-21
BRPI0912294A2 (pt) 2015-10-20
PT3216793T (pt) 2019-05-30
IL209061A0 (en) 2011-01-31
AU2009248993C1 (en) 2013-10-03
CR11757A (es) 2010-11-30
JP2011522802A (ja) 2011-08-04
DK3216793T3 (da) 2019-05-06
BRPI0912294B1 (pt) 2019-11-12
AU2009248993A1 (en) 2009-11-26
PE20091957A1 (es) 2009-12-30
HK1203199A1 (en) 2015-10-23
ES2728163T3 (es) 2019-10-22
CN104230831A (zh) 2014-12-24
AU2009248993B2 (en) 2011-07-07
CN104230831B (zh) 2016-08-24
CU23887B1 (es) 2013-04-19
AR071909A1 (es) 2010-07-21
AP2010005453A0 (en) 2010-12-31
NZ588526A (en) 2012-08-31
US8748421B2 (en) 2014-06-10
RS58724B1 (sr) 2019-06-28
US20130109670A1 (en) 2013-05-02
HRP20190680T1 (hr) 2019-06-14
EA020317B1 (ru) 2014-10-30
GEP20125589B (en) 2012-07-25
US8445486B2 (en) 2013-05-21
KR20110002485A (ko) 2011-01-07
TW201008949A (en) 2010-03-01
US8217036B2 (en) 2012-07-10
EA201071232A1 (ru) 2011-06-30
CA2721692C (en) 2014-01-14
US20090304692A1 (en) 2009-12-10
ZA201007204B (en) 2011-12-28
ECSP10010623A (es) 2010-12-30
HK1157328A1 (en) 2012-06-29
TR201906123T4 (tr) 2019-05-21
CL2009001273A1 (es) 2009-11-27
CU20100229A7 (es) 2011-11-15
CY1121699T1 (el) 2020-07-31
IL209060A0 (en) 2011-01-31
JP4948677B2 (ja) 2012-06-06
EP2300483A1 (en) 2011-03-30
TW201011010A (en) 2010-03-16
US20090291079A1 (en) 2009-11-26
US20130005723A1 (en) 2013-01-03
TWI389906B (zh) 2013-03-21
ME01111B (me) 2013-03-20
AP2010005452A0 (en) 2010-12-31
US20150011752A1 (en) 2015-01-08
PA8828201A1 (es) 2009-12-16
CA2721710A1 (en) 2009-11-26
CO6311070A2 (es) 2011-08-22
AU2009248997A1 (en) 2009-11-26
DK2294072T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
AR071909A1 (es) Compuesto triazina, composicion que lo comprende y metodo para elaborar el compuesto
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR084408A1 (es) Compuestos de purina y 7-deazapurina substituidos
AR076171A1 (es) Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central.
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR071856A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
PE20142366A1 (es) Compuestos triazolo como inhibidores de pde 10
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR075005A1 (es) Derivados de sulfonamida
AR075071A1 (es) COMPUESTOS DERIVADOS DE SULFONAMIDAS , USO DE LOS MISMOS PARA LA PREPARACIoN DE MEDICAMENTOS , COMPOSICIONES FARMACÉUTICAS Y PROCESO DE PREPARACIoN DE LOS MISMOS
AR080167A1 (es) Macrociclos como inhibidores del factor xia
AR044005A1 (es) Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
PE20181519A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
AR070255A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1)
AR085406A1 (es) Oxazinopteridinas y oxazinopteridinonas n-sustituidas
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR086086A1 (es) Derivados glucosidos y usos de los mismos
AR092288A1 (es) Ligandos del receptor ep1
AR068466A1 (es) Cianoisoquinolina
AR084361A1 (es) Compuestos de aril triazol con actividad antitumoral

Legal Events

Date Code Title Description
FG Grant, registration